Obsidian Therapeutics Files 8-K Amendment Adding Pro Forma Financials

What Happened
Obsidian Therapeutics, Inc. (OBX) filed Amendment No. 1 to a previously submitted Form 8-K on August 14, 2026 to provide additional financial statements and exhibits under Item 9.01 (Financial Statements and Exhibits). The amendment includes pro forma financial information (Exhibit 99.3) related to the company’s mergers; the pro forma data is presented for illustrative purposes only and is not intended to represent actual or projected future results. No other changes were made to the original 8-K.

Key Details

• Filing: Amendment No. 1 to Form 8-K filed August 14, 2026 (Item 9.01: Financial Statements and Exhibits).
• Exhibit added: Pro forma financial information presented as Exhibit 99.3.
• Purpose: Pro forma figures are illustrative only and do not purport to show what combined company results would have been or will be.
• Timing: The amendment was filed within the SEC’s permitted 71‑day window for such updates to the original filing.

Why It Matters
This amendment supplies the additional financial disclosures investors need to evaluate the accounting impact of Obsidian’s announced mergers. The inclusion of pro forma financials can help investors understand how prior results would look on a combined basis, but the company explicitly cautions these figures are illustrative and not forecasts. Investors should treat the pro forma data as supplemental information and rely on the company’s audited reports and future filings for definitive financial results.